Loading, Please Wait...
YONKERS, N.Y., May 08, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, today announced that it will host an R&D Symposium with widely recognized infectious disease clinicians on the broad potential of direct lytic agents as anti-infectives, with a focus on the methicillin-resistant Staphylococcus aureus (MRSA) data from the Phase 2 trial of exebacase, on Tuesday, May 14, 2019, at 8:30 a.m. EDT in New York.
The event will be led by Roger Pomerantz, M.D., F.A.C.P., President, Chief Executive Officer and Chairman of ContraFect and will feature presentations from Vance G. Fowler, M.D., Professor of Medicine in the Division of Infectious Diseases at Duke University, and G. Ralph Corey, M.D., Professor of Medicine in the Division of Infectious Diseases, Vice Chair for Education and Global Health in the School of Medicine, Gary Hock Professor of Global Health, and Director of the Hubert-Yeargan Center for Global Health at Duke University. Members of ContraFect’s management team, Cara Cassino, M.D., the Chief Medical Officer and EVP of Research and Development and Raymond Schuch, Ph.D., the Vice President of Research, will provide an in-depth review of the data from the exebacase Phase 2 study and an overview of the Company’s discovery programs targeted towards Gram-negative pathogens.
A live webcast of the event will be available on the Investors & Media section of the Company’s website at www.contrafect.com. The presentation will also be available as an archived webcast for a limited time.
ContraFect is a biotechnology company focused on discovering and developing differentiated biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin platform and through the use of other novel agents. Lysins are a new therapeutic class of bacteriophage-derived, recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. We believe that the properties of our lysins will make them suitable for targeting antibiotic-resistant organisms, such as Staph aureus and Pseudomonas aeruginosa (P. aeruginosa), which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. Our lead lysin candidate, exebacase is completing a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis and is the first lysin to enter clinical studies in the U.S.
This press release contains, and our officers and representatives may make from time to time, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding the Company’s ability to discover and develop biological therapies for life-threatening, drug-resistant infectious diseases, statements made regarding the R&D Symposium, whether Dr. Fowler and Dr. Corey are widely recognized infectious disease clinicians, whether direct lytic agents have the broad potential to be anti-infectives, statements regarding Phase 2 study data and MRSA data, the Company’s ability to address life threatening infections using its therapeutic product candidates from its lysin platform and through the use of other novel agents, whether lysins are a new therapeutic class of bacteriophage-derived, recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, and whether the properties of the Company’s lysins will make them suitable for targeting antibiotic-resistant organisms, such as Staph aureus and P. aeruginosa. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Relations Contacts
Stern Investor Relations